Expert Insights

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Nataliya Uboha, MD, PhD, discusses the role cytoreductive surgery with HIPEC has for patients with gastric cancers that have peritoneal carcinomatosis.

In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.

In this video, our experts explore therapy options for patients with high-risk HER2-positive breast cancer, sharing their views on anthracycline-based therapies, neratinib, and immunotherapy for these patients, and discussing data from the...

In this video, a panel of experts discuss the management of patients with stage 1, HER2-positive breast cancer, sharing data from several trials in this space, including the APT, ADEPT, and ATEMPT 2.0 trials.

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Nataliya Uboha, MD, PhD, discusses the role immunotherapy can have in the treatment of patients with microsatellite instability.

In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Michael Overman, MD, explores whether or not there is a role for immune therapy in the treatment of patients with proficient mismatch repair colorectal...

Jennifer Eads, MD, comments on the results from the ESOPEC trial, which found perioperative chemotherapy improved survival for patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation.

Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.

Pier Franco Conte, MD, shares insights on the phase 3 A-BRAVE trial evaluating adjuvant avelumab for high-risk patients with early triple-negative breast cancer.